MOUD Buprenorphine Sublocade denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for moud buprenorphine sublocade are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Sublocade as Duplicate Therapy — and Why You Can Appeal

A duplicate-therapy denial means UnitedHealthcare's review system flagged that another buprenorphine product (typically a sublingual film or tablet) is already active on your profile, and the plan considers the injectable extended-release formulation (Sublocade) redundant. This logic misses the clinical point: the injectable formulation exists precisely because it eliminates the compliance, diversion, and absorption variability problems associated with daily oral administration. These are distinct clinical tools, not duplicates.

## Why This Denial Is Appealable

The FDA approved Sublocade as a separate product with a distinct delivery mechanism for patients with moderate-to-severe opioid use disorder (OUD). Your prescriber's decision to switch formulations is a medical judgment — not a plan administrator's — and duplicate-therapy logic that ignores formulation differences is a reviewable clinical determination. Federal law gives you a structured path to challenge it.

## Your Federal Appeal Rights

• Internal appeal (ERISA §503 / ACA §2719): You have the right to a full-and-fair internal review. Submit a written appeal within the timeframe shown on your denial letter (commonly 180 days for ERISA plans, but verify yours).
• External review: After exhausting internal review — or if UHC misses its decision deadline — you may request independent external review. Under ACA §2719 and NAIC model rules, you generally have up to four months from the internal denial notice to file for external review.
• Expedited / urgent appeal: If continuing on a sublingual formulation poses a safety or adherence risk, ask your prescriber to document medical urgency and request an expedited determination (typically 72-hour turnaround).

## Concrete Appeal Steps

1. Obtain the denial letter and identify the exact basis cited. 2. Pull UnitedHealthcare's published coverage policy for extended-release injectable buprenorphine — available on uhcprovider.com — and note every criterion listed. 3. Have your prescriber draft a medical-necessity letter that directly addresses why the injectable formulation is clinically distinct and necessary for this patient (e.g., adherence history, diversion risk, prior sublingual trial outcomes). 4. Compile the documentation package below. 5. File the written internal appeal and request peer-to-peer review simultaneously.

## Documentation to Gather

• Diagnosis confirmation: DSM-5 diagnosis of moderate-to-severe OUD in the chart, with dates.
• Prior formulation history: Dates, doses, adherence records, and outcomes for any sublingual buprenorphine product already tried — specifically documenting why extended-release injection addresses a gap.
• Clinical severity: Recent assessment notes showing current clinical picture.
• Prescriber medical-necessity letter: Should explain that this is a clinically distinct formulation, not a redundant one, referencing applicable SAMHSA and ASAM treatment guidelines generically.
• Criteria-mapping table: List each requirement from UHC's published coverage policy; answer each with the corresponding chart fact or prescriber attestation.

## Criteria-Mapping Structure

Copy every bullet point from UHC's coverage policy for Sublocade into a table. In the right column, cite the exact chart entry, lab result, or prescriber note that satisfies each criterion. Leave nothing unaddressed — reviewers deny on missing documentation as often as on clinical grounds.